The healthcare burden of autoimmune hepatitis (AIH) in the United States has not been characterized. We previously showed that AIH disproportionately affects people of color in a single hospital system. The current study aimed to determine whether the same disparity occurs nationwide.
INTRODUCTION
Autoimmune hepatitis (AIH) is an uncommon immune-mediated liver disorder, typically characterized by elevated transaminases and immunoglobulin levels, autoantibodies, and histologic evidence of interface hepatitis ( 1 ) . Th e etiology of AIH is unknown, although a genetic predisposition, a dysregulated immune system, and environmental factors are thought to be involved ( 2 ) . Epidemiological research has largely come from single centers in the United States and studies in racially/ethnically homogeneous countries (3) (4) (5) (6) (7) . More information about aff ected populations and the healthcare burden of AIH in the United States is needed.
AIH is a disease seen in people of all races and ethnicities ( 8 ) . A few retrospective, single-center studies have suggested that the clinical presentation and outcome of AIH diff er by race ( 7, 9, 10 ) . We previously reported that in our racially/ethnically diverse center, AIH cases disproportionately aff ected the people of color (abstract, Th e Liver Meeting 2015).
In order to characterize the burden of AIH on the community and on the healthcare system and to further investigate racial/ ethnic disparities, we assessed hospital admissions for AIH as captured by the Nationwide Inpatient Sample (NIS). We hypothesized that the people of color are disproportionately hospitalized for AIH and suff er worse outcomes during those hospitalizations, compared to whites. inpatient information typically collected from discharge summaries. Data variables include patient demographics, hospital characteristics, discharge diagnoses and procedures, total charges and payment source, length of stay, and discharge status. Patient demographics, including ethnicity, are self-reported.
Prior to 2012, the NIS raw data sampled 20% of all participating US community hospitals and recorded all discharge records within those hospitals. A community hospital is defi ned by the American Hospital Association to be all non-Federal general, and other specialty hospitals…included are public hospitals and academic medical centers. Consequently, Veterans Aff airs hospitals, Indian Health Service hospitals, and other Federal hospitals are excluded. Short-term rehabilitation hospitals, long-term non-acute care hospitals, psychiatric hospitals, and alcoholism/chemical dependency treatment facilities were also excluded. Beginning with the 2012 data, which was included in our analysis, the NIS was redesigned to systematically sample 20% of discharge records from all HCUPparticipating hospitals. Under the previous sample design, in situations where certain types of conditions are concentrated in certain types of hospitals, there were considerable variation in national estimates of healthcare utilization depending on which hospitals were selected for the sample. For example, breast cancer treatment is concentrated in specialty hospitals, and estimates will vary depending on whether specialty hospitals were chosen in the 20% sample. We have to assume that AIH treatment is not concentrated in certain types of hospitals and that AIH hospitalizations from before 2012 and during 2012 are equally representative samples.
Between 
Data points
Each discharge record was labeled with several discharge diagnoses. Th e allowed number of discharge diagnoses varied by state with as few as 9 in Louisiana and as many as 61 in Indiana. We considered the fi rst discharge diagnosis to be the primary discharge diagnosis and to be the most relevant diagnosis for the hospitalization. Prior validation studies have shown that the discharge diagnosis accurately captures the reason for hospitalization, e.g., ischemic heart disease ( 12 ), chronic obstructive pulmonary disease ( 13 ), pulmonary embolism ( 14 ) , primary biliary cirrhosis ( 15 ) , and hepatitis B and C ( 16 ) . Th ere is also a precedence for using the primary and secondary discharge diagnosis to identify hospitalizations for constipation ( 17 ) , hepatitis A ( 18 ), esophageal variceal bleeding ( 19 ) , and cholangitis ( 20 ) . We analyzed hospitalizations labeled with a primary discharge diagnosis of International Classifi cation of Diseases, 9th revision, Clinical Modifi cation (ICD-9-CM) code 571.42 Autoimmune Hepatitis, a code instituted in 2008. Prior to 2008, AIH was coded under ICD-9 code 571.49 Chronic Hepatitis, which included active chronic hepatitis, fi brous, hypertrophic, interstitial, lupoid, plasma cell, post-necrotic, recurrent, and Waldenstrom's hepatitis. In order to analyze a larger sample of AIH-related hospitalizations for the mortality analysis, we analyzed hospitalizations labeled with the ICD-9 code for AIH as one of its top fi ve discharge diagnoses.
Data period
For our cross-sectional analysis of demographics, hospital course, and mortality, we analyzed the 2008-2012 hospitalizations with a primary discharge diagnosis of 571.42. Th e number of AIH hospitalizations rapidly increased from 2008 to 2010 potentially due to adoption of the new code, rather than an actual increase in incidence or prevalence. As a result, for our analysis of hospitalization rate, we excluded 2008 and 2009 and only analyzed 2010-2012 hospitalizations with a primary discharge diagnosis of 571.42.
Data variables
We included the following variables in our analysis: age, gender, race/ethnicity, median income for patient's zip code of residence, payer/insurance, metro/micropolitan residence, and United States region. Age was categorized into six groups (<20, 20-29, 30-39, 40-49, 50-59, >60) for the chi-square analysis and as a continuous variable for the logistic regression. Racial/ethnic groups included white, black, Latino, Asian/Pacifi c Islander, Native American, and other. Metropolitan residence was defi ned as a county with a population greater than 50,000 and was stratifi ed into four categories (central counties with a population more than one million, akin to "inner cities"; fringe counties with a population more than one million, akin to "suburbs"; counties with a population <1 million but >250,000; and counties with a population <250,000 but >50,000); micropolitan residence was defi ned as a county with a population <50,000. Th e course of each hospitalization for AIH was assessed using up to four diagnoses listed aft er the primary discharge diagnosis and the fi rst fi ve procedures.
Analysis

Demographics:
In the bivariate analysis of AIH and non-AIH hospitalizations, we compared demographic and hospital characteristics using the χ 2 -test for categorical variables and analysis of variance for continuous variables. Hospital course: We compared clinical presentation, length of stay, and mortality rate of AIH hospitalizations between the diff erent races/ethnicities. Hospitalization rate: We calculated the rate of AIH hospitalizations and the rate of all-cause hospitalizations per 100,000 persons by dividing the 3-year total number of race-specifi c AIH and all-cause hospitalizations by the 3-year total race-specifi c population during 2010-2012. Race-specifi c populations were obtained from the US Census Bureau ( https://www.census.gov/topics/population/data. html ). We reported risk ratios for each race as compared to whites as reference. We also calculated the race-specifi c rate of AIH hospitalization per 100,000 hospitalizations by dividing the 3-year total number of AIH hospitalizations by the three-year total number of hospitalizations during [2010] [2011] [2012] AIH, autoimmune hepatitis; CI, confi dence interval. a All includes self-reported race "Other" and discharges for which race information was not available. Table 2c ).
Predictors of AIH vs. non-AIH hospitalization
We assessed the eff ect of individual and community factors on hospitalization for AIH vs. for non-AIH primary diagnoses ( Table 3 ). Aft er controlling for all variables listed, race, gender, insurance status, and community income were associated with
We also performed a sensitivity analysis of AIH-related hospitalizations, in which AIH appears anywhere within the top fi ve discharge diagnoses, as opposed to only the fi rst discharge diagnosis. All statistical analyses were performed using STATA Statistical Soft ware: Release 13.0, StataCorp LP, College Station, TX, USA. Th is study relies on public, de-identifi ed data and does not constitute research involving human subjects; it complies with Title 45 of the USCode of Federal Regulations. As such, it was exempt from the Institutional Review Board approval.
RESULTS
Th e National Inpatient Sample data from 2008 to 2012 captured 1,933 hospitalizations with a primary discharge diagnosis of AIH. Using the sampling weights provided by HCUP, this represents 9,258 (95% confi dence interval (CI), 8,471-10,044) AIH hospitalizations during the study period. Table 4 describes the hospitalizations with a primary discharge diagnosis of AIH in terms of concomitant conditions, procedures, length of stay, and mortality. At least one complication associated with decompensated cirrhosis or hepatocellular carcinoma occurred in 36% of AIH hospitalizations. Th e two most common complications were ascites (16% of AIH hospitalizations) and hepatic encephalopathy (10% of AIH hospitalizations). At least one complication occurred in 38% of white, 30% of black, 38% of Latino, 17% of Asian, and 23% of native american AIH hospitalizations. At least one concomitant autoimmune disorder occurred in 11% AIH hospitalizations. Lupus was the most common, included on 3% of AIH hospitalizations, followed by primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC) at 2%. Hepatitis C was present in 1% of AIH hospitalizations. A majority (53%) of AIH hospitalizations included at least one procedure. Percutaneous liver biopsy (28% of AIH hospitalizations) and paracentesis (13% of AIH hospitalizations) were the most common procedures. Th e average length of stay was 7 days.
Patient demographics
Hospital course/presentation
Th e overall mortality of AIH hospitalizations was 4.2%. Th e unadjusted in-hospital mortality rate was 3.3% for white AIH hospitalizations, 5.7% for black, 4.6% for Latino, 0% for API, 11.58% for Native Americans ( P =0.23).
Predictors of mortality
Th e results of a multivariable logistic regression model of mortality during hospitalizations for AIH are shown in Table 5 and Figure 1 . Among AIH hospitalizations, black race increased the odds of mortality (OR 2.81, 95% CI 1.43, 5.47) aft er controlling for age, gender, payer, residence, zip code income, hospital region, and cirrhosis.
In the broadened sensitivity analysis of all AIH-related hospitalizations, for which AIH appeared anywhere in the top fi ve discharge diagnoses, black race was still an independent predictor of mortality (OR 2.60, 95% CI 1.51, 44.7) aft er controlling for the above factors ( Table 6 ).
DISCUSSION
In this study, we found that AIH hospitalizations disproportionately aff ect black and Latino Americans. Furthermore black race is an independent predictor of mortality during these hospitalizations.
Our fi nding that the average annual hospitalization rate 2010-2012 for AIH is 0.73 per 100,000 in the United States is comparable to AIH hospitalization rates published elsewhere. A tertiary care referral center in Spain reported 0.8 cases per 100,000 and a secondary care referral center in the United Kingdom 
LIVER
Disparities in AIH Hospitalizations
study's hospitalization rate and mortality fi ndings further support this emerging trend. Th e absolute number of AIH hospitalizations was higher among whites than the absolute number of AIH hospitalizations among blacks or Latinos, 3,526 compared to 1,159 and 1,110, respectively. However, aft er controlling for the diff erent race-specifi c population sizes and the larger white population, the rate of AIH hospitalization was higher among blacks and Latinos as compared to whites, 1.01 and 0.71 as compared to 0.6 AIH hospitalizations per 100,000 race-specifi c population, respectively. Th e absolute rate reported 3.0 cases per 100,000 (refs 21,22 ) . By comparison, other studies using the NIS data set reported hospitalization rates of 0.29 per 100,000 for hepatitis A; 13.81 per 100,000 for hepatitis C; and 99 per 100,000 for hepatocellular carcinoma ( 18, 23, 24 ) .
Prior studies have already suggested that ethnicity is an important factor in the presentation, disease course, and outcome of AIH. Our group previously reported single-center fi ndings that blacks and Latinos composed a percentage of the AIH hospitalization population that is disproportionate to the racial profi le of the all-cause hospitalization population. Our diff erences are small, but the relative risk ratios are statistically signifi cant and represent a troubling racial disparity on a national scale.
Th is disparity could refl ect at least two alternative scenarios: (i) Blacks and Latinos utilize healthcare resources and hospitalizations for all diseases, not only for AIH, at a higher rate compared to whites. However, we found that the all-cause hospitalization rate for blacks was only 19% (95% CI 1.189-1.190) higher than whites. Th is diff erence is too small to account for the 69% (95% CI 1.58-1.81) diff erence in the black vs. white AIH hospitalization rate. Furthermore, the all-cause hospitalization rate for Latinos was 29% (95% CI 0.708-0.709) lower than whites, disproving this scenario. Th e disproportionate AIH hospitalization rate among blacks and Latinos cannot be explained simply by a higher level of healthcare utilization by these two racial communities. (ii) AIH is more prevalent among blacks and Latinos. Th e AIH hospitalization rate per population is a refl ection of two more specifi c rates: AIH prevalence in the population and the AIH hospitalization rate among patients with AIH. Th e NIS only includes cases of AIH that required hospitalization. Consequently, we did not have data on the non-hospitalized AIH population and could not quantify the complete AIH population. As a result, we are unable to determine whether there is a disparity in AIH prevalence. However, our study shows that, at some level, black and Latino communities bear a greater burden of AIH hospitalizations. Combined with our fi nding that AIH contributed to a higher proportion of all-cause hospitalizations among the race-specifi c black and Latino population as compared to the white population, more resources are needed to manage AIH for these two communities.
Th ere was no statistically signifi cant diff erence in the AIH inhospital mortality rate by race. However, aft er adjusting for covariates with a multivariable model, black race signifi cantly increased the odds of mortality both in hospitalizations with AIH as a primary diagnosis and as a related diagnosis. While we controlled for gender, race, payer, residence, zip code income, region, and the presence of cirrhosis, the small number of AIH in-hospital fatalities limited the number of variables that could be included in the multivariable regression. With a larger sample and larger number of AIH fatalities, we would have included the size and teaching status of the hospital, liver complications, and other concomitant comorbidities. We decided not to remark on the in-hospital mortality rate observed in API or Native Americans due to the small number of AIH hospitalizations for these two racial groups.
Prior studies have suggested potential biological and socioeconomic factors driving these disparities. Prior reports have shown that blacks and Latinos experience more advanced fi brosis associated with AIH, suggesting a predisposition for more aggressive disease progression ( 4, 5 ) . In a single tertiary-care community hospital, Wong et al. ( 7 ) found biopsy-confi rmed cirrhosis in 55% of Latino AIH patients compared to 30% of whites and 29% of Asians. In a retrospective single-center 10-year analysis, Verma et al. ( 10 ) found that black AIH patients were more likely to present with cirrhosis and liver failure and suff ered higher mortality rates compared to non-blacks.
Genetic and pharmacogenomic diff erences may also aff ect treatment response and disease progression. Th e metabolism of prednisone is dependent on cytochrome P450 3A4 and P-glycoprotein transporter. Polymorphisms that aff ect the expression or function Recognizing this limitation, we did not attempt to assess trends in AIH hospitalization over time. A major limitation of the NIS is the lack of personal identifi cation codes in the discharge records. Th is meant the NIS data could not track individual patients across time or settings and a single individual could have been hospitalized multiple times for AIH. Th erefore, we cannot say if black and Latino individuals with AIH are hospitalized more oft en than white Americans. Th erapy information was also unavailable and diff erences refl ecting inadequate initiation or escalation of immunosuppression will need further study.
Despite the limitations of the NIS data set, these results are a major contribution to our understanding of AIH in the United States. Blacks and Latinos have a higher hospitalization rate for AIH than whites, and correcting for covariates, black race increases the odds of in-hospital mortality during hospitalizations for AIH. Disparities in healthcare utilization and outcomes of AIH exist on a national scale. Future studies should further elucidate the reasons behind these racial disparities in order of the cytochrome P450 3A4 or P-glycoprotein can aff ect the drug concentration, remission with therapy, and need for hospitalization. Th e diff erent prevalence of specifi c polymorphisms among the races may contribute to the disproportionate hospitalization rates.
Diff erences in the access and quality of care may delay diagnosis and result in inadequate or escalation of immunosuppressive therapy and suboptimal management of AIH in blacks and Latinos. Kim et al. ( 25 ) showed that patients with consistent access to primary care prior to diagnosis of AIH had better transplant-free overall survival than those without. Echkoff et al. ( 26 ) found that black patients were referred for liver transplantation at later stages of endstage liver compared to white patients. Nguyen et al. ( 27 ) found that blacks and Latinos hospitalized for complications of portal hypertension were less likely to undergo a palliative shunt or liver transplant than whites. While data about primary care access and disease stage is unavailable in the NIS, diff erences in care and implicit bias may contribute to the racial disparities we identifi ed ( 28 ) .
Prior research studies on race and AIH have largely been retrospective case series with no information on socioeconomic status. Since race may be a confounder in the relationship between socioeconomic status and disease outcomes, the current study was able to account for some aspects of socioeconomic status with the NIS variables. Adjusting for the median income of the patient's zip code of residence and insurance/payer, as well as urban or rural residence, our analysis still found race/ethnicity to be signifi cantly Odds ratio (95% CI)
to design targeted interventions, particularly as the number of people of color in the United States grows. 
